Does rituximab really induce hepatitis C virus reactivation?
Ennishi
Daisuke
D
Yokoyama
Masahiro
M
Terui
Yasuhito
Y
Takeuchi
Kengo
K
Ikeda
Kazuma
K
Tanimoto
Mitsune
M
Hatake
Kiyohiko
K
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D016174:Hepacivirus / Q000502:physiology*; D006526:Hepatitis C / Q000821:virology*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008297:Male; D049268:Positron-Emission Tomography; D012367:RNA, Viral / Q000032:analysis; D000069283:Rituximab; D014057:Tomography, X-Ray Computed; D014775:Virus Activation / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D012367:RNA, Viral; D000069283:Rituximab